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Background: This study is to evaluate the predictive value of FDG-PET (PET) in pediatric and adolescent patients
suffering from non-Hodgkin lymphoma (pNHL) in comparison to information provided by conventional imaging
methods (CIM).
Methods: Imaging was performed at baseline and at interim (after 2 cycles of chemotherapy). The response
assessment in PET was carried out visually and semi-quantitatively, the latter one by use of percentage decrease in
SUVmax from baseline to interim (ΔSUVmax). The PET-based results were compared to the findings by CIM.
Progression-free survival (PFS) was analyzed using Kaplan-Meier curves (KM) and log-rank test.
Results: The final study included 16 patients (mean follow-up time, 60.2 months (range, 4.0 to 85.7 months)). Relapse
occurred in four patients. Visual PET compared to CIM revealed higher sensitivity (3/4 vs 1/4) and NPV (6/7 vs 10/13),
and equal PPV (3/9 vs 1/3), but lower specificity (6/12 vs 10/12) and accuracy (9/16 vs 11/16). False-positive findings in
PET at interim were predominantly observed in patients presenting bulky disease (5/6), whereas CIM was true-negative
in all of these cases. KM analyses revealed no significant differences in 5-year PFS neither for CIM (76.9% vs 66.7%;
p = 0.67) nor for visual PET (85.7% vs 66.7%; p = 0.34) nor for ΔSUVmax (88.9% vs 57.1%; p = 0.12).
Conclusions: The predictive value of iPET in pediatric patients suffering from NHL was limited due to considerably
high amount of false-positive findings, especially in patients suffering from bulky disease. However, due to our limited
sample size, final conclusions cannot be drawn and, thus, call for further evaluation of PET in pNHL in larger and more
homogenous patient series.
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A deeper understanding of the biological behavior and
the awareness that different subtypes of non-Hodgkin
lymphoma (NHL) in pediatric and adolescent patients
require different treatment strategies resulted in major
improvements of cure rates ranging from more than
80% for lymphoblastic lymphoma up to 90% or even
higher for mature B cell lymphoma [1]. However, the* Correspondence: christian.furth@med.ovgu.de
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in any medium, provided the original work is pfirst-line treatment with curative intent is associated
with considerable high toxicity due to dose-intense treat-
ment strategies. On the other hand, in case of relapse,
the chance for curative treatment is dramatically de-
creased due to unsatisfactory salvage regimen options.
In order to facilitate a tailored, risk-adapted therapy,
positron emission tomography (PET) using the tracer
[18F]fluorodeoxyglucose (FDG) might contribute to iden-
tify patients with increased risk of relapse during or after
treatment. Additionally, FDG-PET may help to distin-
guish patients with favorable outcome, who might bene-
fit from a de-escalation of treatment intensity resulting
in a reduction of treatment-related toxicity.open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Patients' data and clinical characteristics












Follicular (WHO grade 2) 1
Involvement (n)
Nodal only 6




Range 4.0 to 85.7
ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B cell lymphoma;
n, count; WHO, World Health Organization.
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pletion of the first 2 cycles of chemotherapy was associ-
ated with a 2-year event free survival (EFS) of 82%,
whereas 2-year EFS was only 43% in FDG-PET-positive
patients [2]. Further on and more recently, in adult pa-
tients with diffuse large B cell lymphoma (DLBCL), Safar
et al. were able to show that the percentaged decrease in
“maximal standardized uptake value” (ΔSUVmax) be-
tween FDG-PET at baseline (bPET) prior to any anti-
neoplastic treatment and FDG-PET at interim (iPET)
can be used to effectively predict 3-year EFS [3]. The
data on this topic are lacking in pediatric and adolescent
patients suffering from NHL (pNHL).
This study presents prospective data on the potential of
FDG-PET for early response assessment after completion
of the first 2 cycles of chemotherapy in pNHL patients.
Early response assessment was carried out (1) visually and
(2) semi-quantitatively by analyses on ΔSUVmax be-
tween bPET and iPET, and (3) by a combination thereof.
The findings in PET and conventional imaging modalities
(CIM) were compared with regard to the prognostic value
for prediction of progression-free survival (PFS).
Methods
Patients
The patients were prospectively recruited within the
bounds of the PET2003 multi-center trial [4,5]. However,
the present analyses are retrospective in nature. The
exclusion criteria were life threatening impairment of
organ function, pregnancy, diabetes mellitus or age
younger than 1 year, respectively. Written informed
consent was obtained from all the patients and/or
parents. The study was carried out in accordance
with the Declaration of Helsinki and the principles of
good clinical practice. The institutional review board
(Charité - Universitätsmedizin Berlin) approved the study
protocol. The approval was granted by the German
Federal Office on Radiation Protection (Bundesamt für
Strahlenschutz) as well as by the corresponding local
authorities. Eighteen pediatric and adolescent patients
(female, 5; male, 13; mean age, 13.5 years (3.7 to 23.2
years)) with NHL (Burkitt/Burkitt-like, n = 7; DLBCL,
n = 5; anaplastic large cell lymphoma (ALCL), n = 3;
T lymphoblastic, n = 2; follicular (WHO grade 2), n = 1)
were analyzed (Table 1). Fifteen patients with newly diag-
nosed NHL were included for analyses, whereas three
patients (patient 8, patient 17, and patient 18) were
included after diagnosis of first relapse of the disease. All
patients were treated according to the appropriate therapy
optimization protocol (TOP) [6-8]. With respect to the
treatment of the recurrent disease, the ALCL-relapse TOP
[9] was used.
The treatment of more than 95% of children with ma-
lignant disease occurs according to TOPs. The patientswith lymphoblastic lymphoma, B-NHL, ALCL, and re-
lapse of ALCL were treated according to the TOPs
Euro-LB 02, B-NHL BFM 2004, ALCL99, and ALCL-
relapse, respectively. All TOPs include intensive multi-
drug chemotherapy for 6 to 9 months. In patients with
lymphoblastic lymphoma, intensive polychemotherapy is
followed by oral maintenance chemotherapy for a total
therapy duration of 2 years.
The mean follow-up was 60.2 months (range, 4.0 85.7
months). The time point of analysis was 8 February 2012.
Due to violation against PET imaging protocol (prolonged
uptake time at baseline PET scan), two patients had
to be excluded from the analyses (patient 4 and patient 6)
(Table 2).
CIM: acquisition and analysis
CIM according to TOPs consisted of contrast-enhanced
magnetic resonance imaging (MRI) of neck, abdomen,
and pelvis; ultrasounds of all the lymph node regions; as
well as a contrast-enhanced thoracic computed tomog-
raphy (CECT). In case of clinical suspicion, additional ex-
aminations by CIM were performed (e.g., lower extremity,
cranial/spinal MRI). The specifications of CIM devices
used and technical requirements needed are published
elsewhere [10]. The data of CIM were reviewed by two
experienced radiologists in a consensus reading, blinded









Response assessment at interim Follow-up
iCIM iPET ΔSUVmax (%)
1 III B lymphoblastic Nodal CRu + 88.1 CR
2 II − DLBCL Nodal PR − 92.2 CR
3 IV − DLBCL Bone/bone marrow SD − 94.5 CR
4 II − Follicular grade 2 Nodal CR + * CR
5 IV B DLBCL Nodal CRu + 60.8 CR
6 IV B DLBCL Nodal CRu + * CR
7 II − Burkitt Nodal CR − 97.2 CR
8 III − ALCL Nodal CR + 47.8 Relapse
9 I B Burkitt Nodal CRu + 91.2 CR
10 IV B Burkitt Nodal CR − 95.2 CR
11 IV − Burkitt Nodal CRu + 90.5 Relapse
12 II B ALCL Nodal CRu − 95.8 CR
13 IV − Lymphoblastic Nodal PR + 88.5 Relapse
14 III − ALCL Nodal CRu + 34.1 CR
15 III B Burkitt Extra nodal (stomach) CR + 50.7 CR
16 IV B Burkitt Nodal CR + 92.5 CR
17 I − DLBCL Nodal CR − 95.8 Relapse
18 IV − Burkitt Nodal CR − 93.5 CR
−, negative; +, positive; *, censored from analyses due to violation against imaging protocol (prolonged tracer uptake time at time point of staging, n = 2);
B, bulky disease present; CIM, conventional imaging modalities; CR, complete response, CRu, complete response unconfirmed; PET, positron emission
tomography; PR, partial response; SD, stable disease.
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dedicated work station (AdvantageWindows 4.1, GE
Medical Systems, Milwaukee, IL, USA). The reading of
CIM for assessment of response status was done in accord-
ance to the criteria defined by an international workshop
[11], including complete response (CR), CR unconfirmed
(CRu), partial response (PR), stable disease (SD), and pro-
gression of disease (PD). The patients with CR or CRu at
interim were judged to be iCIM-negative, whereas the pa-
tients stated to have PR, SD, or PD were categorized to be
iCIM-positive.
PET: acquisition and reconstruction analysis
FDG-PET scanning was performed for staging prior to
any administration of anti-neoplastic treatment (bPET)
and after completion of the first 2 cycles of chemother-
apy (iPET), with a minimum time interval between the
preceding chemotherapy and iPET of 14 days. Whole-
body FDG-PET examinations were performed according
to the recommendations of the “European Association
of Nuclear Medicine” guidelines [12] (activity at bPET:
mean, 222 MBq (standard deviation (SDev), ±71.7 MBq);
activity at iPET: mean, 250 MBq (SDev, ±75.3 MBq)).
The PET protocol consisted of an 8-hour fasting period,
followed by confirmatory blood sugar testing to ensurethat the glucose values were within the normal range
(reference, <6.1 mmol/L).
The scanners used were dedicated full-ring PET systems
(ECAT EXACT 921, 47, Siemens, Erlangen, Germany;
ECAT EXACT HR+, Siemens/CTI, Knoxville, TN, USA)
or a hybrid PET/CT (Biograph16, Siemens, Erlangen,
Germany). The children were consistently examined with
the same device at interim as used for staging. All the PET
scans were performed in two-dimensional mode (six to
eight bed positions with 8 min of emission and 4 min of
transmission) (FDG uptake time at bPET: mean, 88 min
(SDev, ±19.1 min); FDG uptake time at iPET: mean, 76
min (SDev, ±20.4 min)). In case of a clinical suspicion, add-
itional PET imaging was performed (e.g., lower extremity).
Regarding the differences in the scanner performance
within this multi-center trial, appropriate scanner calibra-
tions had been performed to keep discrepancies at mini-
mum level. The PET data were reconstructed using
ordered subset expectation maximization with 4 iterations
and 16 subsets, using a matrix of 128 × 128 for the stand-
alone PET scanner and a matrix of 256 × 256 for the PET/
CT device. The emission data were corrected for decay,
dead time, scatter, and random coincidences. The parame-
ters for the PET acquisition were in accordance with the
recommendations given by Boellaard et al. [13].
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For visual evaluation, maximum intensity whole-body
projections as well as coronal, axial, and sagittal slices
were reconstructed from the PET datasets (e.soft4.0,
Leonardo workstation, Siemens Medical Solutions,
Erlangen, Germany). Regarding the performed FDG-
PET/CT studies, the acquired functional and morpho-
logical datasets were read separately. Thus, each method
was evaluated independently without prior knowledge of
the PET or CIM findings, respectively. The PET data were
evaluated in consensus by two experienced nuclear medi-
cine specialists blinded to the results of CIM and clinical
data. The PET reading was carried out in accordance with
criteria defined by the International Harmonization Pro-
ject in lymphoma (IHP) [14]. The PET scans were assessed
visually and judged positive in case of detection of focally
increased uptake above the surrounding tissue or in-
creased uptake as compared to mediastinal blood pool ac-
tivity which was used as region of reference in terms of
FDG accumulation. However, mild and diffusely increased
FDG uptake with an intensity lower than or equal to that
of mediastinal blood pool structures was considered to be
PET-negative.
PET: semi-quantitative analysis
For semi-quantitative analyses, attenuation-corrected
PET datasets were used only. Lesions with pathologic-
ally increased FDG uptake obtained in the visual re-
sponse assessment were determined by SUVmax using
a “region of interest” (ROI) feature of a dedicated
software tool (rover® v2.0.31, ABX GmbH, Radeberg,
Germany). Within all the lesions measured in bPET,
the highest SUVmax (SUVmax bPET) was documented
and then re-evaluated in iPET (SUVmax iPET) at that
same site in the respective patient. In case of a complete
metabolic response at iPET as assessed by visual means, a
minimized standard mask consisting of three voxels was
placed in the center of the initially affected lymphoma
site. The relative SUVmax differences were calculated
as ΔSUVmax = (SUVmax bPET − SUVmax iPET) /
SUVmax bPET × 100.
PET: analyses on combined assessment
Patients were defined to be positive in combined assess-
ment if iPET was visually positive and ΔSUVmax was
less than or equal to the corresponding cutoff in receiver
operator characteristics (ROC) analyses. All the other
combinations were stated to be negative in combined
iPET assessment.
Standard of reference
To establish a standard of reference, the results of CIM
and PET were finally verified by an interdisciplinary
tumor board. For verification of the lesion status, allstaging and follow-up examinations, histopathology of
biopsies, and clinical data including the serial follow-up
examinations were used. All patients underwent regular
follow-up investigations, including physical examina-
tions, blood tests, chest X-ray, and ultrasound quarterly
during the first year, half yearly during the second year,
and once a year thereafter. Suspicion of relapse was
confirmed by biopsy and histopathological examin-
ation. Progression-free survival (PFS) was defined as
the time from enrollment in PET2003 trial to first pro-
gression, relapse, and either death, whatever the cause,
or last follow-up.
Statistics
The data analyses were carried out using the software R
version 2.14.0 (R Foundation for Statistical Computing,
Vienna, Austria; http://www.R-project.org). The clinical
characteristics and quantitative data for the obtained SUVs
are expressed as median ± SDev, unless otherwise speci-
fied. Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV), as well as accur-
acy, were calculated using standard formulas. The dif-
ferences of diagnostic parameters were tested according
to the method of Bennett [15]. A ROC analysis was
performed to analyze the association of ΔSUVmax and
the recurrence of disease. The optimal ROC threshold
was defined by the point with the minimal distance to
100% sensitivity and 100% specificity. The PFS was ana-
lyzed using Kaplan-Meier curves and log-rank test. All
tests were two sided, and a p value less than 0.05 was
referred to be significant.
Results and discussion
Two patients (patient 4 and patient 6) had to be ex-
cluded from the analyses due to violation against PET
imaging protocol (prolonged uptake time at bPET)
(Table 2). In four of the remaining 16 patients, relapse of
disease occurred (patient 11, 3.1 months; patient 13, 7.4
months; patient 8, 24.3 months; patient 17, 25.7 months).
Two patients died during follow-up due to progression of
disease (patient 11, 4.0 months; patient 13, 28.8 months)
(Table 1). The lesions used for response assessment at in-
terim were localized at nodal sites in 14 patients and in 2
patients at extra nodal sites (Table 2).
Visual response assessment: iCIM versus iPET
Concerning visual assessment, iCIM and iPET revealed
concordant findings in six patients (TP, n = 1; TN, n = 4;
FN, n = 1). In two patients, iPET was TP, whereas iCIM
was FN; vice versa, in two patients, iPET was TN, and
iCIM revealed FP findings. In the remaining six cases,
iCIM was TN, whereas iPET revealed FP findings.
iPET revealed higher sensitivity (3/4) compared to
iCIM (1/4) and higher NPV (iPET, 85.7% (6/7) vs iCIM,
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iCIM (iCIM, 83.3% (10/12) vs iPET, 50.0% (6/12)). Com-
parable values were obtained for PPV (iCIM, 33.3% (1/3)
vs iPET, 33.3% (3/9)). In total, accuracy was higher in
iCIM (11/16, 68.8%) when compared to iPET (9/16,
56.2%). A comprehensive overview of the diagnostic values
obtained is given in Table 3. No significant differences were
observed (sensitivity, p = 0.157; specificity, p = 0.157; NPV,
p = 0.480; PPV, p = 1).
Semi-quantitative analyses of FDG uptake reduction
induced by the first 2 cycles of polychemotherapy
Median SUVmax at initial staging was 17.1 (range, 8.5 to
49.7). After 2 cycles of polychemotherapy, a median
SUVmax reduction of 91.7% (range, 34.1% to 97.2%)
was observed, corresponding to a median SUVmax of
2.0 (range, 0.7 to 10.6) at interim. The ROC analysis of
SUVmax reduction at interim for identification of relapse
patients showed an AUC of 0.58 (p = 0.684) with a corre-
sponding optimal cutoff value at 90.5%. Three of the
seven patients with SUVmax reduction ≤90.5% suffered
relapse of disease. Sensitivity and specificity for the pre-
diction of relapse in Δ analyses were 75.0% (3/4) and
66.7% (8/12), respectively (PPV, 42.9% (3/7); NPV, 88.9%
(8/9); accuracy, 68.8% (11/16)). No statistical differences
were seen when the diagnostic values of the ΔSUVmax




TP (n) 1 3 3
FP (n) 2 6 4
TN (n) 10 6 8
FN (n) 3 1 1
Sensitivity, % (CI) 25.0 75.0 75.0
(1.3-70.0) (30.1-98.7) (30.1-98.7)
Specificity, % (CI) 83.3 50.0 66.7
(55.2-95.3) (25.4-74.6) (39.1-86.2)
PPV, % (CI) 33.3 33.3 42.9
(1.7-79.2) (12.1-64.6) (15.8-75.0)
NPV, % (CI) 76.9 85.7 88.9
(49.7-91.8) (48.7-99.3) (56.5-99.4)
Accuracy, % (CI) 68.8 56.2 68.8
(44.4-85.8) (33.2-76.9) (44.4-85.8)
Δ, percentaged decrease of SUVmax between staging and restaging; CI,
confidence interval; FN, false-negative; FP, false-positive; iCIM, conventional
imaging modalities performed at interim; iPET, positron emission tomography
performed at interim; n, count; NPV, negative predictive value; PPV, positive
predictive value; SUVmax, maximum standardized uptake value; TN, true-negative;
TP, true-positive.interpretation (sensitivity, p = 0.157; specificity, p = 0.414;
PPV, p = 0.732; NPV, p = 0.294).
Combined response assessment by FDG uptake reduction
and visual response assessment by iPET
The combined approach showed no improvement as all
the patients judged to be negative in visual iPET assess-
ment showed a ΔSUVmax ≥90.5% (ROC cutoff ).
Prediction of progression-free survival
The Kaplan-Meier curves for 5-year PFS are given in
Figure 1 (Figure 1A,B,C) and showed no significant differ-
ences in PFS, neither for CIM (76.9% vs 66.7%; p = 0.67)
nor for visual iPET analyses (85.7% vs 66.7%; p = 0.34) nor
for ΔSUVmax analyses (88.9% vs 57.1%; p = 0.12).
The role of interim PET in NHL is discussed contro-
versially with respect to the response to therapy assess-
ment [16-20]. Visual response assessment in pNHL
using dedicated, well-defined response criteria was lim-
ited to the concordant detection of patients suffering
early relapse, whereas patients with late relapse were not
reliably detectable in a blinded multi-center read [21]. In
adult patients suffering from NHL (i.e., DLBCL), the re-
sults suggest that the use of SUVmax in addition to vis-
ual analyses substantially improves the prognostic value
of iPET [22].
In our pediatric population, the use of semi-quantitative
response assessment by means of ΔSUVmax analyses in-
dicated a slightly improved sensitivity as well as a slightly
improved NPV for the detection of patients with subse-
quent relapse. However, CIM was superior to ΔSUVmax
concerning specificity, whereas PPV was poor for both
approaches. The Kaplan-Meier curves showed no sig-
nificant differences concerning the prediction of PFS
neither for CIM nor for visual iPET assessment nor for
ΔSUVmax analyses.
The data addressing the role of interim or end of treat-
ment PET in pNHL are rare. Regarding the prediction of
response to therapy, Edeline et al. [23] reported that in-
formation gathered from end of treatment PET (visual
assessment) in ten pediatric patients suffering from NHL
did not provide further information to accurately predict
outcome. In their series, only one out of five PET-
positive pNHL patients showed a relapse, whereas four
out of five PET-negative patients remained in remission.
In contrast, Depas et al. [24] found an excellent specifi-
city for PET when performed during treatment (range,
PET after 2 to 3 cycles of chemotherapy) as there were
no false-positives in their analyses. However, PET failed
to identify the recurrence of disease in all three patients
suffering relapse, suggesting a more specific but not sen-
sitive read out. Similar observations were done by Mody
et al. [25], as PET was not suitable to detect recur-
rence of disease in the CNS. However, close location
Figure 1 Kaplan-Meier curves for response assessment by conventional imaging modalities and positron emission tomography.
Progression-free survival according to the information provided by the response assessment using (A) conventional imaging modalities in
accordance to the recommendations given by Cheson et al. [11], (B) visual response assessment of interim PET using the recommendations
given by Juweid et al. on behalf of the IHP [14], and (C) relative decrease in SUVmax between baseline and interim PET. PFS, progression-free
survival; CR, complete response; CRu, complete response unconfirmed; PR, partial response; SD, stable disease; ΔSUVmax, decrease in maximum
standardized uptake value between staging and interim PET; neg., negative; pos., positive.
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take is a well-known pitfall in PET imaging. A more
recent study investigating 34 pNHL patients found a
PPV of 41.2% (7/17 patients) and a NPV of 85.7% for
interim PET/CT analyses [26]. The poor PPV (33.3%,
3/9 patients) and high NPV (85.7%, 6/7) for the visual
iPET response assessment in our study is comparable
to the results presented by Bakhshi et al. [26]. However,
more important and similar to our results, they also
found no significant discordance in prediction of PFS
when findings of CECT and PET/CT were compared to
the true outcome of each patient (CECT, p = 0.18; PET/
CT, p = 0.083) [26].
This particular observation is in contrast to the data
on iPET in adults suffering from DLBCL reported re-
cently. Safar et al. [3] reported that 3-year PFS in 112
adults suffering from DLBCL was significantly higher
in iPET-negative patients (84%) compared to those in
iPET-positive patients (47%, p < 0.0001) using visual
response assessment. However, the results from the
LNH2007-3B trial [22] showed that the visual response
assessment by iPET was not suitable to significantly im-
prove the prediction of 2-year PFS (iPET-negative, 77%;
iPET-positive, 73%; p = 0.586), whereas ΔSUVmax
analyses showed significant improvement of 2-year
PFS (iPET-negative ΔSUVmax ≤66%, 57% vs iPET-
positive ΔSUVmax >66%, 77%; p = 0.028) [22]. The latter
one was confirmed by Safar et al. for the prediction of 3-
year PFS using the same cutoff in ΔSUVmax analyses
(iPET-negative ΔSUVmax ≤66%, 77% vs iPET-positive
ΔSUVmax >66%, 38%; p = 0.002) [3]. However, in our
study, the use of ΔSUVmax analyses with a threshold
of 90.5% as revealed by ROC analysis was not suitableto significantly predict PFS (p = 0.120). Applying the
ΔSUVmax cutoff revealed by Casasnovas et al. [22]
and Safar et al. [3] (both iPET-negative ΔSUVmax ≤66%)
on the present patient series, no significant differences in
5-year PFS were observed too (both groups 75%, data not
shown). Overall, the performance of ΔSUVmax analyses
in our study was disappointing compared to the re-
sults in adults. As ROC analysis showed no significant
discrimination concerning the prediction of response,
the Kaplan-Meier curves have to be interpreted with
caution.
The present study revealed a high amount of false-
positive findings in PET, all being true-negative in
CIM. Due to not specific nature of the tracer used,
there is a high likelihood for false-positive PET find-
ings during treatment (e.g., brown fatty tissue, fat ne-
crosis, inflammation, reactive lymph nodes, thymus
rebound, and diffuse bone marrow uptake after admin-
istration of hematopoietic growth factors) [27-29]. A
high number of false-positive findings (26/38) has also
been reported by Moskowitz et al. in a prospective series
[19]. Serial histology confirmed in only 5 out of 38
patients with viable lymphoma cells. In the remaining 33
patients, progression of the disease occurred in seven
patients [19].
In the present study, the false-positive findings in iPET
were predominantly observed in patients presenting
bulky disease (visual iPET, 5/6 patients). The iPET false-
positive findings in these patients may be explained by a
stromal reaction due to influx of inflammatory cells (i.e.,
macrophages) as it has been demonstrated in a mouse
model [30]. The uptake due to non-lymphoma-related
cells might be associated with the extension of the bulky
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in reading and interpreting of iPET in patients present-
ing bulky disease at baseline.
Due to ethical reasons, serial histological confirmation
of iPET-positive findings in children is beyond ethical
reasons; however, it was performed in one patient in our
series (Table 2; patient 9, Figure 2). The histological veri-
fication of his iPET-positive finding showed a reactive in-
filtrate of macrophages, particularly foamy cells and a
few lymphoid aggregates, but no viable lymphoma cells
[21]. Further on, Figures 3 and 4 illustrate two exem-
plary cases for iPET-positive findings (Table 2; patient
5 and patient 15) which turned out to be false-positive
(Figures 3 and 4). In both cases, increased tracer uptake
within the residual at interim may be attributed to the
influx of inflammatory cells.
Nevertheless, as iPET is acquired after 2 cycles of
chemotherapy while that particular PET result is com-
pared to the result after the entire treatment, the possi-
bility of a “true-positive iPET signal” (generated by at
that time still viable lymphoma tissue that was only later
successfully eradicated by subsequent treatment) cannot
be safely excluded.
Several limitations of our study have to be addressed:
(1) The number of patients included in our analyses is
too small, and the variety of histological subtypes is
too big to draw final conclusions; thus, further pro-
spective investigations in prospectively enrolled seriesA
C
Figure 2 Twelve-year-old boy suffering from Burkitt lymphoma (Table
SUVmax at baseline was 30.9 and decreased to 2.7 at interim. Visual iPET as
analyses indicated a sufficient decrease (ΔSUVmax, 91.2%). CIM (B, D) confi
examination of the visual iPET-positive finding ruled out viable lymphomawith proper sample sizes are needed. (2) Use of different
PET devices may confound the results of the pre-
sented study as it may contribute to SUV variability.
However, this problem might be overcome by close
adherence to standardized protocols as initiated by the
European Association of Nuclear Medicine (i.e., EARL
FDG-PET/CT Accreditation) [13]. (3) Sub-summation of
various stages (e.g., early, intermediate, and advanced)
hamper an unbiased comparison to data in adults as
that data were obtained in more homogeneous series.
However, homogeneous pediatric patient series with suffi-
cient sample sizes are difficult to obtain even in multi-
center trials. (4) Lastly, the optimal time point of PET
imaging in pNHL with positive findings minimally fal-
sified by inflammatory or reactive reactions still has to
be determined.Conclusions
In our explorative analyses, the predictive value of PET
for response assessment at interim in pediatric patients
suffering from NHL was limited. Whereas the underper-
formance of visual iPET assessment was expectable, espe-
cially the poor performance of the ΔSUVmax approach
was a disappointing finding. Especially in patients with
bulky disease, the PET approaches mainly failed to predict
the outcome. However, due to the small number of in-
cluded patients, final conclusions cannot be drawn and,B
D
2, patient 9). The lymphoma was localized in the left axilla (A, B).
sessment was judged to be iPET-positive (C), whereas ΔSUVmax
rmed a complete response unconfirmed at interim. Histological
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Figure 3 Fourteen-year-old boy suffering from Burkitt-lymphoma (Table 2, patient 15). The lymphoma was primarily localized in the stomach
(A, B, C). Initial SUVmax was 21.5 and decreased to 10.6 at interim time point (A and D; ΔSUVmax, 50.7%). Also, in the visual iPET analysis (D), the
patient was judged to be positive (please note activation of brown adipose tissue at interim marked with black arrow heads (D). Using CIM, a decrease
of 100% between baseline (arrows in B and C) and interim time points was shown (arrow heads in E and F). No further measurable disease was
detected by CIM. Thus, a complete response was indicated by CIM. The patient is in ongoing remission. Therefore, both ΔSUVmax and visual iPET
analyses were false-positive when compared to true outcome, whereas CIM was true-negative.
A C
B D
Figure 4 Sixteen-year-old girl suffering from a diffuse large B cell lymphoma (Table 2, patient 5). The lymphoma was primary localized in
the left lung and pleura (A, B). Initial SUVmax was 10.7 and decreased to 4.2 at interim (A and C; visual iPET-positive, ΔSUVmax 60.7%). Thus, PET
approaches suggested residual disease at interim. CIM findings at interim showed massive reduction in size (arrow head, D) and disappearance of
all other foci corresponding to a complete response unconfirmed. The patient is in ongoing remission (CIM, true-negative; visual iPET, false-positive;
ΔSUVmax, false-positive).
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http://www.ejnmmires.com/content/3/1/71thus, call for further evaluation of PET in pNHL in larger
and more homogenous patient series.
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